Ignite Creation Date:
2025-12-24 @ 9:42 PM
Ignite Modification Date:
2026-01-02 @ 8:22 AM
Study NCT ID:
NCT00483132
Status:
COMPLETED
Last Update Posted:
2007-06-06
First Post:
2007-06-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
Sponsor:
French Innovative Leukemia Organisation
Organization:
Study Overview
Official Title:
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.
High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).
High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).
Detailed Description:
Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: